Literature DB >> 35679138

Early growth response 1 transcription factor is essential for the pathogenic properties of human endometriotic epithelial cells.

Vineet K Maurya1, Maria M Szwarc1, Rodrigo Fernandez-Valdivia2, David M Lonard1, Song Yong3, Niraj Joshi3, Asgerally T Fazleabas3, John P Lydon1.   

Abstract

Although a non-malignant gynecological disorder, endometriosis displays some pathogenic features of malignancy, such as cell proliferation, migration, invasion and adaptation to hypoxia. Current treatments of endometriosis include pharmacotherapy and/or surgery, which are of limited efficacy and often associated with adverse side effects. Therefore, to develop more effective therapies to treat this disease, a broader understanding of the underlying molecular mechanisms that underpin endometriosis needs to be attained. Using immortalized human endometriotic epithelial and stromal cell lines, we demonstrate that the early growth response 1 (EGR1) transcription factor is essential for cell proliferation, migration and invasion, which represent some of the pathogenic properties of endometriotic cells. Genome-wide transcriptomics identified an EGR1-dependent transcriptome in human endometriotic epithelial cells that potentially encodes a diverse spectrum of proteins that are known to be involved in tissue pathologies. To underscore the utility of this transcriptomic data set, we demonstrate that carbonic anhydrase 9 (CA9), a homeostatic regulator of intracellular pH, is not only a molecular target of EGR1 but is also important for maintaining many of the cellular properties of human endometriotic epithelial cells that are also ascribed to EGR1. Considering therapeutic intervention strategies are actively being developed for EGR1 and CAIX in the treatment of other pathologies, we believe EGR1 and its transcriptome (which includes CA9) will offer not only a new conceptual framework to advance our understanding of endometriosis but will also furnish new molecular vulnerabilities to be leveraged as potential therapeutic options in the future treatment of endometriosis.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35679138      PMCID: PMC9339520          DOI: 10.1530/REP-22-0123

Source DB:  PubMed          Journal:  Reproduction        ISSN: 1470-1626            Impact factor:   3.923


  93 in total

1.  Tissue remodeling and nonendometrium-like menstrual cycling are hallmarks of peritoneal endometriosis lesions.

Authors:  Florian Sohler; Anette Sommer; David L Wachter; Abbas Agaimy; Oliver M Fischer; Stefan P Renner; Stefanie Burghaus; Peter A Fasching; Matthias W Beckmann; Ulrike Fuhrmann; Reiner Strick; Pamela L Strissel
Journal:  Reprod Sci       Date:  2012-08-09       Impact factor: 3.060

2.  Early growth response 1 transcriptionally primes the human endometrial stromal cell for decidualization.

Authors:  Maria M Szwarc; Lan Hai; William E Gibbons; Qianxing Mo; Rainer B Lanz; Francesco J DeMayo; John P Lydon
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-31       Impact factor: 4.292

Review 3.  Clinical practice. Endometriosis.

Authors:  Linda C Giudice
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

Review 4.  A modified baboon model for endometriosis.

Authors:  Asgerally T Fazleabas; Allison Brudney; Bilgin Gurates; Daniel Chai; Serdar Bulun
Journal:  Ann N Y Acad Sci       Date:  2002-03       Impact factor: 5.691

Review 5.  The roles of carbonic anhydrases IX and XII in cancer cell adhesion, migration, invasion and metastasis.

Authors:  Simonas Daunys; Vilma Petrikaitė
Journal:  Biol Cell       Date:  2020-09-21       Impact factor: 4.458

6.  Creation of immortalised epithelial cells from ovarian endometrioma.

Authors:  Y Bono; S Kyo; M Takakura; Y Maida; Y Mizumoto; M Nakamura; K Nomura; T Kiyono; M Inoue
Journal:  Br J Cancer       Date:  2012-02-21       Impact factor: 7.640

7.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

8.  A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors.

Authors:  Paul C McDonald; Stephen Chia; Philippe L Bedard; Quincy Chu; Michael Lyle; Liren Tang; Madhu Singh; Zaihui Zhang; Claudiu T Supuran; Daniel J Renouf; Shoukat Dedhar
Journal:  Am J Clin Oncol       Date:  2020-07       Impact factor: 2.787

9.  EGR1-mediated linc01503 promotes cell cycle progression and tumorigenesis in gastric cancer.

Authors:  Zhonghua Ma; Xiangyu Gao; You Shuai; Xiaolong Wu; Yan Yan; Xiaofang Xing; Jiafu Ji
Journal:  Cell Prolif       Date:  2020-11-03       Impact factor: 6.831

Review 10.  Nonhormonal therapy for endometriosis based on energy metabolism regulation.

Authors:  Hiroshi Kobayashi; Hiroshi Shigetomi; Shogo Imanaka
Journal:  Reprod Fertil       Date:  2021-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.